Felodipine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Felodipine

Examples of brand names: Munobal [DE]

ATC code: C08CA02

Main use (for orientation): Hypertension

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Felodipine. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Do not transfer grapefruit or strong-inhibitor effects to CBD; consider formulation. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Extensive CYP3A4 first-pass breakdown; predominantly inactive metabolites.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Cannabinoid-related exposure or blood-pressure effects have not been measured.

Context: The formulation assessed is a prolonged-release product.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [V2_LABEL_D0211]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Extensive CYP3A4 first-pass breakdown; predominantly inactive metabolites.

Source: FELODIPINE TABLET, EXTENDED RELEASE FELOPDIPINE (FELODIPINE) TABLET, EXTENDED RELEASE [WESTMINSTER PHARMACEUTICALS, LLC] [V2_LABEL_D0211]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Do not transfer grapefruit or strong-inhibitor effects to CBD; consider formulation.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[V2_LABEL_D0211] FELODIPINE TABLET, EXTENDED RELEASE FELOPDIPINE (FELODIPINE) TABLET, EXTENDED RELEASE [WESTMINSTER PHARMACEUTICALS, LLC]

Original source / bibliographic reference

Authors: WESTMINSTER PHARMACEUTICALS, LLC

Year: 2023

Source type: US SPL / DailyMed regulatory product labelling

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility